Stronger follow-up therapy for AR-high triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a stronger follow-up treatment (intensification) for women with a specific type of triple-negative breast cancer that has high androgen receptors. It is for those who did not have a complete response to chemotherapy before surgery and do not have a BRCA1/2 mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have triple-negative breast cancer that is high in androgen receptors (AR).
- You had surgery for early-stage breast cancer and your tumor did not completely disappear after at least 4 rounds of chemo before surgery.
- You do not have a harmful BRCA1/2 gene mutation.
- Your organs (like blood, liver, and kidneys) are working well enough, and your surgical wounds are healed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for a specific type of advanced triple-negative breast cancer. It compares the study drug given alone versus with another medicine, to see which is more effective in slowing the cancer down.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a targeted therapy (olaparib) and chemotherapy (paclitaxel) before surgery for people with an aggressive type of early breast cancer called triple-negative breast cancer. It is for those whose tumors have a specific genetic feature called HRD-positive, which may make the cancer more sensitive to these treatments.
Hear when a new Breast Cancer Females trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.